Polaris AI Pharma Rises on News of FDA Approval and Expanded Pancreatic Cancer Clinical Scope for Investee 'Alpha Tau'

Polaris AI Pharma is showing strength. This is believed to be due to news that Alpha Tau Medical, a Nasdaq-listed company in which Polaris AI Pharma has invested, has received supplemental approval from the U.S. FDA to expand the clinical scope for pancreatic cancer.

As of 9:57 a.m. on May 7, Polaris AI Pharma was trading at 7,330 won, up 5.01% from the previous day.

With this FDA approval, Alpha Tau will begin additional enrollment of a gemcitabine/nab-paclitaxel combination treatment group in the U.S. multi-center pilot clinical trial (IMPACT) for pancreatic cancer patients, expanding the total clinical trial size to 40 participants. With this expansion, the company has secured a development pathway that covers the full range of standard treatment options for pancreatic cancer, and patient enrollment for the trial is expected to be completed in the third quarter of this year.

Meanwhile, Polaris AI Pharma is accelerating its efforts to strengthen its vertical AI capabilities specialized in the pharmaceutical domain through strategic investment in QuadMedicine and joint development of the pharmaceutical-focused AI solution "Ask Doc for Pharma" with Polaris Office.

This content was produced with the assistance of AI translation services.